European Medicines Agency updates treatment recommendations because of continued Fabrazyme shortage

View source ↗

Summary

EMA updates treatment recommendations due to ongoing Fabrazyme shortage, adjusting guidance on management for patients requiring enzyme replacement therapy.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Fabry Disease

Drugs mentioned

• FABRAZYME (Agalsidase beta)